SNSE
Closed
Sensei Biotherapeutics Inc
8.85
+0.27 (+3.15%)
Last Update: 01 Jul 2025 23:00:00
Yesterday: 8.58
Day's Range: 8.58 - 8.97
Send
sign up or login to leave a comment!
When Written:
1.53
Sensei Biotherapeutics Inc. is a clinical-stage biopharmaceutical company that focuses on developing personalized cancer immunotherapies. The company's proprietary ImmunoPhage platform uses bacteriophages, which are viruses that infect bacteria, to deliver tumor-specific antigens to the immune system. This approach aims to stimulate an immune response that targets and destroys cancer cells.
Sensei Biotherapeutics was founded in 2014 and is headquartered in Gaithersburg, Maryland. The company's lead product candidate, SNS-301, is being evaluated in a Phase 1/2 clinical trial for the treatment of squamous cell carcinoma of the head and neck. Sensei Biotherapeutics is also developing other product candidates for the treatment of various types of cancer, including lung and ovarian cancer.
The company has partnerships with several academic institutions and pharmaceutical companies, including the University of Maryland, the University of Pittsburgh, and Merck & Co. Sensei Biotherapeutics has raised over $150 million in funding from investors, including F-Prime Capital, New Enterprise Associates, and Abingworth.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Sensei Biotherapeutics was founded in 2014 and is headquartered in Gaithersburg, Maryland. The company's lead product candidate, SNS-301, is being evaluated in a Phase 1/2 clinical trial for the treatment of squamous cell carcinoma of the head and neck. Sensei Biotherapeutics is also developing other product candidates for the treatment of various types of cancer, including lung and ovarian cancer.
The company has partnerships with several academic institutions and pharmaceutical companies, including the University of Maryland, the University of Pittsburgh, and Merck & Co. Sensei Biotherapeutics has raised over $150 million in funding from investors, including F-Prime Capital, New Enterprise Associates, and Abingworth.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!